Fig. 4.

APG-115 enhances anti-PD-1 antibody mediated tumor suppression in Trp53^wt, Trp53^mut and Trp53^−/− syngeneic mouse tumor models. APG-115 was tested alone and in combination with anti-PD-1 antibody in mice subcutaneously implanted with Trp53^wt MH-22A (a-d; n = 8), Trp53^mut MC38 (e-g; n = 10), or Trp53^−/− MH-22A (h-j; n = 10) tumor cells. APG-115 was orally administered every day in Trp53^wt MH-22A models or every other day in both Trp53^mut MC38 and Trp53^−/− MH-22A models. Anti-PD-1 antibody was administered intraperitoneally BIW. Treatments were conducted for 3 weeks in Trp53^wt MH-22A and Trp53^mut MC38 models, and for 12 days in Trp53^−/− MH-22A model. Data representing at least two independent experiments were presented as the mean of tumor volumes of mice in each group (A, E, H) or tumor volumes for individual mice (B, C, D, F, G, I and J). The control groups were treated with APG-115 vehicle (A) or isotype antibody plus vehicle (I + V; E and H)